Indeed, sema3F and sema3B have been characterized as bona fide tumor suppressors of lung cancer [98,99,100,101], and sema3A has been found to function as an endogenous angiogenesis inhibitor that is down-regulated during tumor progression [88]. The gene discussed is SEMA3F; the disease is lung carcinoma.